There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Knight Therapeutics (KHTRF – Research Report) and Phasebio Pharmaceuticals (PHAS – Research Report) with bullish sentiments.
Knight Therapeutics (KHTRF)
In a report released today, Endri Leno from National Bank maintained a Buy rating on Knight Therapeutics, with a price target of C$7.75. The company’s shares closed last Thursday at $4.69.
Leno has an average return of
According to TipRanks.com, Leno is ranked #7238 out of 8019 analysts.
Currently, the analyst consensus on Knight Therapeutics is a Strong Buy with an average price target of $5.69.
See Insiders’ Hot Stocks on TipRanks >>
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on KHTRF:
- Jasper Therapeutics Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
- OneWater Marine Announces the Appointment of Steve Roy to its Board of Directors
- Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
- Grindrod Shipping Holdings Ltd. Announces Date for Its Second Quarter and First Half 2022 Financial Results Release
- Covenant Logistics Group Announces Filing of Universal Shelf Registration Statement on Form S-3
